Vismodegib API Manufacturers & Suppliers

Vismodegib (CAS number 879085-55-9) is an orally active small molecule indicated for the treatment of adults with metastatic basal cell carcinoma (BCC) or locally advanced BCC that has recurred following surgery, in patients who are not candidates for surgery or radiation. The drug received initial regulatory approval from the FDA in January 2012 and from the EMA in July 2013, with subsequent approvals in multiple countries.

Pharmacologically, vismodegib functions as a selective inhibitor of the Hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). The Hedgehog pathway is critical in embryogenesis, regulating cell growth, differentiation, apoptosis, and self-renewal. In adult tissues, this pathway is largely silenced except in hair follicles, skin, and stem cells. Aberrant activation of the pathway, due to mutations, leads to uncontrolled proliferation of basal skin cells and is implicated in BCC pathogenesis. By antagonizing SMO, vismodegib prevents the activation and nuclear translocation of downstream transcription factors, thereby inhibiting Hedgehog target gene expression and tumor growth.

Key pharmacodynamic observations include no clinically significant QT interval prolongation after 7 days of dosing at 150 mg once daily. The drug is classified within organic compounds known as benzanilides, featuring an anilide group with a benzene substitution.

Safety considerations include a boxed warning for embryo-fetal toxicity; vismodegib may cause embryo-fetal death or severe birth defects. Additional adverse effects of note are severe cutaneous and musculoskeletal reactions. Pediatric exposure has been associated with premature fusion of the epiphyses. These factors necessitate careful patient evaluation and monitoring.

From a pharmacokinetic standpoint, vismodegib is a substrate and inhibitor of several cytochrome P450 enzymes (including CYP2C19, CYP2C8, and CYP2C9) and is also a substrate for P-glycoprotein and BCRP/ABCG2 transporters. This profile underscores potential drug-drug interaction risks requiring thorough assessment during clinical management.

API procurement for vismodegib demands strict adherence to regulatory quality standards due to its complex synthetic process and critical role in oncology therapeutics. Suppliers should provide comprehensive documentation including purity analysis, residual solvents, and stability data, ensuring compliance with pharmacopeial requirements and Good Manufacturing Practice guidelines. Consistent quality control is essential to support clinical efficacy and safety.